Kineret, Anakinra News

Arthritis drugs are a significant part of most arthritis treatment regimens. Arthritis patients are often eager to learn about newer arthritis drugs.

Remember when Grandma used to say, "don't go out in the cold; you'll get sick"? It turns out that she was right for a small number of people who have a condition called familial cold autoinflammatory syndrome , in which individuals are afflicted by rash, fever, joint pain and flu-like symptoms after exposure to cold conditions as mild as an ...

Biovitrum AB today announced an agreement with Amgen to expand Biovitrum's Kineret license to include certain orphan indications.

Biovitrum AB has taken a significant step in its goal to become a fully integrated, specialty pharmaceutical firm focused on niche indications, with an SEK3.656 billion cash-and-shares acquisition of Swedish Orphan International AB.

XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced the expansion of its development strategy for its XOMA 052 antibody to interleukin-1 beta to include effects on cholesterol lowering, reducing plaque deposits and damage to heart muscle and resulting long-term effects that can lead to heart attack, stroke and ...

As a treatment for rheumatoid arthritis, there is "moderate-level" evidence that the immunomodulator abatacept is safe and effective, conclude the co-authors of a Cochrane Intervention Review posted online October 4. Abatacept inhibits the co-stimulation of T cells and disrupts the inflammatory chain of events that lead to joint inflammation, pain ...

Main Category: Arthritis / Rheumatology Also Included In: Pain / Anesthetics Article Date: 08 Oct 2009 - 1:00 PDT More studies that directly compare the effectiveness of different biologic drugs for rheumatoid arthritis are needed, say Cochrane Researchers.

More studies that directly compare the effectiveness of different biologic drugs for rheumatoid arthritis are needed, say Cochrane Researchers.

Major advances have taken place in recent years in our understanding and the evidence base of JIA.

July 8, 2009. Biovitrum AB has entered an exclusive distribution and marketing agreement with Megapharm Ltd.

Speaking to the American Medical Association last month, President Obama waxed enthusiastic about countries that "spend less" than the U.S. on health care.

Copenhagen, Denmark, Friday 12 June 2009: First line treatment with anakinra receptor antagonist), results in a 'good' clinical response in patients newly diagnosed with systemic onset juvenile idiopathic arthritis , and restores the deficient IL-18 response of natural killer cells*, according to a new study presented today at PReS 2009, a joint ...

U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Institute of Arthritis and Musculoskeletal and Skin Diseases Embargoed for Release: Wednesday, June 3, 2009, 5:00 p.m. EDT CONTACT: Trish Reynolds, 301-496-8190, SCIENTISTS DISCOVER NEW GENETIC IMMUNE DISORDER IN CHILDREN Your immune system plays an ...

In autoinflammatory diseases, however, the immune system goes awry, causing unprovoked and dangerous inflammation.

Mutations in the interleukin-1 receptor antagonist gene are associated with an autoinflammatory disease involving skin and bone, and symptoms can be resolved by recombinant IL1RN , according to two studies in the June 4 issue of the New England Journal of Medicine .